Aylin C Bonifacino
Overview
Explore the profile of Aylin C Bonifacino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Uchida N, Nassehi T, Drysdale C, Gamer J, Yapundich M, Bonifacino A, et al.
Mol Ther
. 2019 Jun;
27(9):1586-1596.
PMID: 31253582
Busulfan conditioning is utilized for hematopoietic stem cell (HSC) depletion in the context of HSC gene-therapy conditioning but may result in insufficient immunosuppression. In this study, we evaluated whether additional...
12.
Demirci S, Mora J, Yapundich M, Drysdale C, Gamer J, Nassehi T, et al.
Exp Hematol
. 2019 Jun;
75:21-25.e1.
PMID: 31173819
Elevated fetal hemoglobin (HbF) is associated with reduced severity of sickle cell disease. Therefore, γ-globin protein levels and F-cell (HbF-positive red blood cell) percentages are used for estimation of clinical...
13.
Uchida N, Fujita A, Hsieh M, Bonifacino A, Krouse A, Metzger M, et al.
Hum Gene Ther Clin Dev
. 2017 Apr;
28(3):136-144.
PMID: 28447889
Steady state bone marrow (BM) is the preferred hematopoietic stem cell (HSC) source for gene therapy in sickle cell disease (SCD) due to the recognized risk of vaso-occlusive crisis during...
14.
Uchida N, Weitzel R, Shvygin A, Skala L, Raines L, Bonifacino A, et al.
Mol Ther Methods Clin Dev
. 2016 Sep;
3:16059.
PMID: 27652288
Reduced intensity conditioning (RIC) is desirable for hematopoietic stem cell (HSC) gene therapy applications. However, low gene marking was previously observed in gene therapy trials, suggesting that RIC might be...
15.
Donahue R, Srinivasula S, Uchida N, Kim I, St Claire A, Duralde G, et al.
Blood
. 2015 Oct;
126(24):2632-41.
PMID: 26492933
Ionizing irradiation is used routinely to induce myeloablation and immunosuppression. However, it has not been possible to evaluate the extent of ablation without invasive biopsy. For lymphoid recovery, peripheral blood...
16.
Kim S, Kim N, Presson A, Metzger M, Bonifacino A, Sehl M, et al.
Cell Stem Cell
. 2014 Apr;
14(4):473-85.
PMID: 24702996
In mice, clonal tracking of hematopoietic stem cells (HSCs) has revealed variations in repopulation characteristics. However, it is unclear whether similar properties apply in primates. Here, we examined this issue...
17.
Uchida N, Evans M, Hsieh M, Bonifacino A, Krouse A, Metzger M, et al.
Mol Ther Nucleic Acids
. 2013 Sep;
2:e122.
PMID: 24045711
Hematopoietic stem cell (HSC) gene therapy using integrating vectors has a potential leukemogenic risk due to insertional mutagenesis. To reduce this risk, a limitation of ≤2 average vector copy number...
18.
Uchida N, Hargrove P, Lap C, Evans M, Phang O, Bonifacino A, et al.
Mol Ther
. 2012 Aug;
20(10):1882-92.
PMID: 22871664
Human immunodeficiency virus type 1 (HIV1) vectors poorly transduce rhesus hematopoietic cells due to species-specific restriction factors, including the tripartite motif-containing 5 isoformα (TRIM5α) which targets the HIV1 capsid. We...
19.
Kean L, Sen S, Onabajo O, Singh K, Robertson J, Stempora L, et al.
Blood
. 2011 Oct;
118(25):6580-90.
PMID: 21989987
In this study, we used the rhesus macaque model to determine the impact that AMD3100 has on lymphocyte mobilization, both alone and in combination with G-CSF. Our results indicate that,...
20.
Goessling W, Allen R, Guan X, Jin P, Uchida N, Dovey M, et al.
Cell Stem Cell
. 2011 Apr;
8(4):445-58.
PMID: 21474107
Hematopoietic stem cells (HSCs) are used in transplantation therapy to reconstitute the hematopoietic system. Human cord blood (hCB) transplantation has emerged as an attractive alternative treatment option when traditional HSC...